Effectiveness of anti-vascular endothelial growth factors in neovascular age-related macular degeneration and variables associated with visual acuity outcomes: Results from the EAGLE study.

<h4>Objective</h4>To assess the overall effectiveness of anti-vascular endothelial growth factor (VEGF) therapy in treatment-naïve patients with neovascular age-related macular degeneration (nAMD) in a clinical practice setting.<h4>Study design</h4>EAGLE was a retrospective,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Giovanni Staurenghi, Francesco Bandello, Francesco Viola, Monica Varano, Giulia Barbati, Elena Peruzzi, Stefania Bassanini, Chiara Biancotto, Vito Fenicia, Claudio Furino, Maria Vadalà, Michele Reibaldi, Stela Vujosevic, Federico Ricci, EAGLE study investigators
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/7cd5ebd5d16f45ec8c3d063c3b733c62
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7cd5ebd5d16f45ec8c3d063c3b733c62
record_format	dspace
spelling	oai:doaj.org-article:7cd5ebd5d16f45ec8c3d063c3b733c622021-12-02T20:08:45ZEffectiveness of anti-vascular endothelial growth factors in neovascular age-related macular degeneration and variables associated with visual acuity outcomes: Results from the EAGLE study.1932-620310.1371/journal.pone.0256461https://doaj.org/article/7cd5ebd5d16f45ec8c3d063c3b733c622021-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0256461https://doaj.org/toc/1932-6203<h4>Objective</h4>To assess the overall effectiveness of anti-vascular endothelial growth factor (VEGF) therapy in treatment-naïve patients with neovascular age-related macular degeneration (nAMD) in a clinical practice setting.<h4>Study design</h4>EAGLE was a retrospective, 2-year, cohort observational, multicenter study conducted in Italy that analyzed secondary data of treatment-naïve patients with nAMD. The primary endpoint evaluated the mean annualized number of anti-VEGF injections at Years 1 and 2. The main secondary endpoints analyzed the mean change in visual acuity (VA) from baseline and variables associated with visual outcomes at Years 1 and 2.<h4>Results</h4>Of the 752 patients enrolled, 745 (99.07%) received the first dose of anti-VEGF in 2016. Overall, 429 (57.05%) and 335 (44.5%) patients completed the 1- and 2-year follow-ups, respectively. At baseline, mean (standard deviation, SD) age was 75.6 (8.8) years and the mean (SD) VA was 53.43 (22.8) letters. The mean (SD) number of injections performed over the 2 years was 8.2 (4.1) resulting in a mean (SD) change in VA of 2.45 (19.36) (P = 0.0005) letters at Year 1 and -1.34 (20.85) (P = 0.3984) letters at Year 2. Linear regression models showed that age, baseline VA, number of injections, and early fluid resolution were the variables independently associated with visual outcomes at Years 1 and 2.<h4>Conclusions</h4>The EAGLE study analyzed the routine clinical practice management of patients with nAMD in Italy. The study suggested that visual outcomes in clinical practice may be improved with earlier diagnosis, higher number of injections, and accurate fluid resolution targeting during treatment induction.Giovanni StaurenghiFrancesco BandelloFrancesco ViolaMonica VaranoGiulia BarbatiElena PeruzziStefania BassaniniChiara BiancottoVito FeniciaClaudio FurinoMaria VadalàMichele ReibaldiStela VujosevicFederico RicciEAGLE study investigatorsPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 9, p e0256461 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Giovanni Staurenghi Francesco Bandello Francesco Viola Monica Varano Giulia Barbati Elena Peruzzi Stefania Bassanini Chiara Biancotto Vito Fenicia Claudio Furino Maria Vadalà Michele Reibaldi Stela Vujosevic Federico Ricci EAGLE study investigators Effectiveness of anti-vascular endothelial growth factors in neovascular age-related macular degeneration and variables associated with visual acuity outcomes: Results from the EAGLE study.
description	<h4>Objective</h4>To assess the overall effectiveness of anti-vascular endothelial growth factor (VEGF) therapy in treatment-naïve patients with neovascular age-related macular degeneration (nAMD) in a clinical practice setting.<h4>Study design</h4>EAGLE was a retrospective, 2-year, cohort observational, multicenter study conducted in Italy that analyzed secondary data of treatment-naïve patients with nAMD. The primary endpoint evaluated the mean annualized number of anti-VEGF injections at Years 1 and 2. The main secondary endpoints analyzed the mean change in visual acuity (VA) from baseline and variables associated with visual outcomes at Years 1 and 2.<h4>Results</h4>Of the 752 patients enrolled, 745 (99.07%) received the first dose of anti-VEGF in 2016. Overall, 429 (57.05%) and 335 (44.5%) patients completed the 1- and 2-year follow-ups, respectively. At baseline, mean (standard deviation, SD) age was 75.6 (8.8) years and the mean (SD) VA was 53.43 (22.8) letters. The mean (SD) number of injections performed over the 2 years was 8.2 (4.1) resulting in a mean (SD) change in VA of 2.45 (19.36) (P = 0.0005) letters at Year 1 and -1.34 (20.85) (P = 0.3984) letters at Year 2. Linear regression models showed that age, baseline VA, number of injections, and early fluid resolution were the variables independently associated with visual outcomes at Years 1 and 2.<h4>Conclusions</h4>The EAGLE study analyzed the routine clinical practice management of patients with nAMD in Italy. The study suggested that visual outcomes in clinical practice may be improved with earlier diagnosis, higher number of injections, and accurate fluid resolution targeting during treatment induction.
format	article
author	Giovanni Staurenghi Francesco Bandello Francesco Viola Monica Varano Giulia Barbati Elena Peruzzi Stefania Bassanini Chiara Biancotto Vito Fenicia Claudio Furino Maria Vadalà Michele Reibaldi Stela Vujosevic Federico Ricci EAGLE study investigators
author_facet	Giovanni Staurenghi Francesco Bandello Francesco Viola Monica Varano Giulia Barbati Elena Peruzzi Stefania Bassanini Chiara Biancotto Vito Fenicia Claudio Furino Maria Vadalà Michele Reibaldi Stela Vujosevic Federico Ricci EAGLE study investigators
author_sort	Giovanni Staurenghi
title	Effectiveness of anti-vascular endothelial growth factors in neovascular age-related macular degeneration and variables associated with visual acuity outcomes: Results from the EAGLE study.
title_short	Effectiveness of anti-vascular endothelial growth factors in neovascular age-related macular degeneration and variables associated with visual acuity outcomes: Results from the EAGLE study.
title_full	Effectiveness of anti-vascular endothelial growth factors in neovascular age-related macular degeneration and variables associated with visual acuity outcomes: Results from the EAGLE study.
title_fullStr	Effectiveness of anti-vascular endothelial growth factors in neovascular age-related macular degeneration and variables associated with visual acuity outcomes: Results from the EAGLE study.
title_full_unstemmed	Effectiveness of anti-vascular endothelial growth factors in neovascular age-related macular degeneration and variables associated with visual acuity outcomes: Results from the EAGLE study.
title_sort	effectiveness of anti-vascular endothelial growth factors in neovascular age-related macular degeneration and variables associated with visual acuity outcomes: results from the eagle study.
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/7cd5ebd5d16f45ec8c3d063c3b733c62
work_keys_str_mv	AT giovannistaurenghi effectivenessofantivascularendothelialgrowthfactorsinneovascularagerelatedmaculardegenerationandvariablesassociatedwithvisualacuityoutcomesresultsfromtheeaglestudy AT francescobandello effectivenessofantivascularendothelialgrowthfactorsinneovascularagerelatedmaculardegenerationandvariablesassociatedwithvisualacuityoutcomesresultsfromtheeaglestudy AT francescoviola effectivenessofantivascularendothelialgrowthfactorsinneovascularagerelatedmaculardegenerationandvariablesassociatedwithvisualacuityoutcomesresultsfromtheeaglestudy AT monicavarano effectivenessofantivascularendothelialgrowthfactorsinneovascularagerelatedmaculardegenerationandvariablesassociatedwithvisualacuityoutcomesresultsfromtheeaglestudy AT giuliabarbati effectivenessofantivascularendothelialgrowthfactorsinneovascularagerelatedmaculardegenerationandvariablesassociatedwithvisualacuityoutcomesresultsfromtheeaglestudy AT elenaperuzzi effectivenessofantivascularendothelialgrowthfactorsinneovascularagerelatedmaculardegenerationandvariablesassociatedwithvisualacuityoutcomesresultsfromtheeaglestudy AT stefaniabassanini effectivenessofantivascularendothelialgrowthfactorsinneovascularagerelatedmaculardegenerationandvariablesassociatedwithvisualacuityoutcomesresultsfromtheeaglestudy AT chiarabiancotto effectivenessofantivascularendothelialgrowthfactorsinneovascularagerelatedmaculardegenerationandvariablesassociatedwithvisualacuityoutcomesresultsfromtheeaglestudy AT vitofenicia effectivenessofantivascularendothelialgrowthfactorsinneovascularagerelatedmaculardegenerationandvariablesassociatedwithvisualacuityoutcomesresultsfromtheeaglestudy AT claudiofurino effectivenessofantivascularendothelialgrowthfactorsinneovascularagerelatedmaculardegenerationandvariablesassociatedwithvisualacuityoutcomesresultsfromtheeaglestudy AT mariavadala effectivenessofantivascularendothelialgrowthfactorsinneovascularagerelatedmaculardegenerationandvariablesassociatedwithvisualacuityoutcomesresultsfromtheeaglestudy AT michelereibaldi effectivenessofantivascularendothelialgrowthfactorsinneovascularagerelatedmaculardegenerationandvariablesassociatedwithvisualacuityoutcomesresultsfromtheeaglestudy AT stelavujosevic effectivenessofantivascularendothelialgrowthfactorsinneovascularagerelatedmaculardegenerationandvariablesassociatedwithvisualacuityoutcomesresultsfromtheeaglestudy AT federicoricci effectivenessofantivascularendothelialgrowthfactorsinneovascularagerelatedmaculardegenerationandvariablesassociatedwithvisualacuityoutcomesresultsfromtheeaglestudy AT eaglestudyinvestigators effectivenessofantivascularendothelialgrowthfactorsinneovascularagerelatedmaculardegenerationandvariablesassociatedwithvisualacuityoutcomesresultsfromtheeaglestudy
_version_	1718375133269196800

Effectiveness of anti-vascular endothelial growth factors in neovascular age-related macular degeneration and variables associated with visual acuity outcomes: Results from the EAGLE study.

Ejemplares similares